New approach to defibrillation may improve cardiac arrest outcomes
Artificial blood vessels
Luiz Bertassoni, D.D.S., Ph.D., founding director of the Knight Cancer Precision Biofabrication Hub and professor in the OHSU Division of Oncological Sciences, has helped develop a method to engineer artificial blood vessels that can support tooth regeneration. The approach could transform future root canal treatments by restoring living tissue instead of removing it. (OHSU)
Artificial blood vessels
Luiz Bertassoni, D.D.S., Ph.D., founding director of the Knight Cancer Precision Biofabrication Hub and professor in the OHSU Division of Oncological Sciences, has helped develop a method to engineer artificial blood vessels that can support tooth regeneration. The approach could transform future root canal treatments by restoring living tissue instead of removing it. (OHSU)
Bertassoni lab: Creating artificial blood vessels
Luiz Bertassoni, D.D.S., Ph.D., founding director of the Knight Cancer Precision Biofabrication Hub and professor in the OHSU Division of Oncological Sciences, has helped develop a method to engineer artificial blood vessels that can support tooth regeneration. The approach could transform future root canal treatments by restoring living tissue instead of removing it. (OHSU)
OHSU study reveals gaps in access to long-term contraceptive supplies
Un estudio de OHSU revela brechas en el acceso a suministros anticonceptivos a largo plazo
OHSU abre un centro global de operaciones para la coordinación de la atención de pacientes a nivel estatal
OHSU opens centralized command center for statewide coordination of patient care
Eric Roeland y equipo
Eric Roeland, M.D., centro, se unió al OHSU Knight Cancer Institute con la misión de desarrollar un programa de investigación centrado en minimizar la toxicidad relacionada con el tratamiento y mejorar la calidad de vida de las personas que viven con cáncer. Roeland es profesor asociado de medicina en la Facultad de Medicina de OHSU. Tanja Glujic-White, izquierda, y Paula Cisternas Labadzinzki, miembros del equipo de investigación clínica en oncología. (OHSU/Christine Torres Hicks)
